Skip to content

US · GHRS · BIOTECHNOLOGY

GH Research PLC (GHRS) intrinsic value and stock valuation

$17.53as of 2026-11-21 · Mkt cap 2.08B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

GH Research PLC DCF and intrinsic value

InvestorsCraft values GHRS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GHRS’s statements →

GH Research PLC Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Dublin, DU D02 NX43 ghres.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-48.26M
20192025
Free cash flow
-$-43.67M
20192025
Total equity
$279.7M+118.1% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-60.68M-$-50.31M-$-41.22M-$-30.55M-$-15.1M
Net income-$-48.26M-$-38.96M-$-35.59M-$-22.46M-$-9.2M
EPSd-$-790.63K-$-748.8K-$-684.16K-$-431.76K-$-176.86K
Operating cash flow-$-43.55M-$-42.28M-$-33.34M-$-26.2M-$-15.28M
Capital expenditure-$-120K-$-50K-$-100K-$-70K-$-100K
Free cash flow-$-43.67M-$-42.33M-$-33.44M-$-26.27M-$-15.39M
Total assets$288.2M$188.3M$226.3M$254.4M$279.9M
Total debt$510K$620K$970K$0.00$0.00
Net debt-$-245.74M-$-100.17M-$-77.45M-$-165.96M-$-276.78M
Total equity$279.7M$179M$219M$249.8M$277.2M
Cash and short-term investments$280.7M$149.3M$161.6M$166M$276.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$340K$0.00$0.00$0.00$0.00
Gross profit-$-340K$0.00$0.00$0.00$0.00
Research and development expenses$38.7M$35M$29.8M$20.5M$8.55M
Selling, general and administrative expenses$21.6M$15M$11.1M$10.1M$6.54M
Other expenses$0.00$290K$280K$10K$10K
Operating expenses$60.3M$50.3M$41.2M$30.6M$15.1M
Cost and expenses$60.7M$50.3M$41.2M$30.6M$15.1M
Interest income$2.62M$2.63M$1.89M$860K$0.00
Interest expense$460K$720K$720K—$10K
Depreciation and amortization$340K$320K$320K$50K$20K
Ebitda-$-47.46M-$-38.6M-$-35.21M-$-22.41M-$-9.17M
Operating income-$-60.68M-$-50.31M-$-41.22M-$-30.55M-$-15.1M
Total other income/expenses, net$12.4M$11.4M$5.63M$8.1M$5.9M
Income before tax-$-48.26M-$-38.96M-$-35.59M-$-22.46M-$-9.2M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-48.26M-$-38.96M-$-35.59M-$-22.46M-$-9.2M
Weighted average shares outstanding$61M$52M$52M$52M$52M
Weighted average diluted shares outstanding$61M$52M$52M$52M$52M
Balance sheet
20252024202320222021
Cash and short-term investments$280.7M$149.3M$161.6M$166M$276.8M
Net receivables$1.29M$1.73M$180K$90K$50K
Inventory$0.00$0.00$0.00-$-90K$3.01M
Total current assets$286M$154.2M$164.1M$168.5M$279.8M
Property, plant and equipment, net$620K$750K$1.07M$100K$80K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$33.3M$61.1M$85.7M$0.00
Total non-current assets$2.25M$34.1M$62.2M$85.8M$80K
Total assets$288.2M$188.3M$226.3M$254.4M$279.9M
Accounts payable$3.77M$3.74M$3.49M$1.87M$880K
Short-term debt$360K$260K$340K$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.38M$8.95M$6.7M$4.55M$2.75M
Long-term debt$150K$370K$630K$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$150K$370K$630K$1.87M$0.00
Capital lease obligations$510K$370K$630K$0.00$0.00
Total liabilities$8.53M$9.32M$7.33M$4.55M$2.75M
Common stock$1.55M$1.3M$1.3M$1.3M$1.3M
Retained earnings-$-154.43M-$-106.45M-$-67.94M-$-32.49M-$-10.04M
Accumulated other comprehensive income (loss)$1.52M-$-7.37M-$-5.86M-$-10.44M-$-5.54M
Total equity$279.7M$179M$219M$249.8M$277.2M
Total investments$34.5M$81.8M$144.3M$85.7M$0.00
Total debt$510K$620K$970K$0.00$0.00
Net debt-$-245.74M-$-100.17M-$-77.45M-$-165.96M-$-276.78M
Cash flow statement
20252024202320222021
Net income-$-48.26M-$-38.96M-$-35.59M-$-22.46M-$-9.2M
Depreciation and amortization$340K$320K$320K$50K$20K
Stock-based compensation$0.00$1.17M$2.29M$1.67M$370K
Change in working capital-$-3.09M$190K$1.65M$2.16M-$-560K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-43.55M-$-42.28M-$-33.34M-$-26.2M-$-15.28M
Investments in property, plant and equipment-$-120K-$-50K-$-100K-$-70K-$-100K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$46.2M$65.1M-$-54.1M-$-84.69M-$-100K
Common stock issued$139.9M$0.00$10K$0.00$309.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$139.7M-$-300K-$-200K$0.00$286.5M
Net change in cash$145.5M$22.4M-$-87.53M-$-110.82M$270.9M
Cash at end of period$246.3M$100.8M$78.4M$166M$276.8M
Operating cash flow-$-43.55M-$-42.28M-$-33.34M-$-26.2M-$-15.28M
Capital expenditure-$-120K-$-50K-$-100K-$-70K-$-100K
Free cash flow-$-43.67M-$-42.33M-$-33.44M-$-26.27M-$-15.39M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About GH Research PLC

        GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

        CEO
        Velichka Valcheva
        Employees
        73
        Beta
        1.29

        Explore

        Frequently asked questions

        What is the intrinsic value of GH Research PLC (GHRS)?

        InvestorsCraft does not currently publish an intrinsic value for GHRS. How the IC value is calculated.

        Is GHRS undervalued?

        InvestorsCraft does not publish an undervaluation signal for GHRS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.